Claims for Patent: 9,365,572

Summary for Patent: 9,365,572

Title:	PI3K and/or mTOR inhibitor
Abstract:	The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, a stereoisomer or a solvate thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X, Y, A and B are as defined in the specification. The present invention further relates to a method for preparing these compounds, a pharmaceutical composition containing these compounds, and a use of these compounds in manufacture of a medicament for treating and/or preventing proliferative diseases. ##STR00001##
Inventor(s):	Wu; Frank (Jinan, CN), Shu; Chutian (Jinan, CN)
Assignee:	Xuanzhu Pharma Co., Ltd. (Jinan, Shandong Province, CN)
Application Number:	14/427,665
Patent Claims:	1. A compound of formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof: ##STR00355## wherein X and Y are each O; A and B are each CH; R.sup.1 is 6- to 10-membered aryl, 5- to 6-membered monocyclic heteroaryl, 9- to 10-membered fused heteroaryl, 5- to 6-membered monocyclic heterocyclic group, or 9- to 10-membered fused heterocyclic group, all of which may be optionally substituted with 1-3 R.sup.7a(s); R.sup.2 is 6- to 10-membered aryl, 5- to 6-membered monocyclic heteroaryl, 9- to 10-membered fused heteroaryl, 5- to 6-membered monocyclic heterocyclic group, or 9- to 10-membered fused heterocyclic group, all of which may be optionally substituted with 1-3 R.sup.7b(s); R.sup.3 is hydrogen; R.sup.4 is hydrogen or C.sub.1-6alkyl, wherein C.sub.1-6alkyl may be optionally substituted with 1-3 substituents selected from halogen, hydroxy and carboxyl; R.sup.7a and R.sup.7b are each independently (1) halogen, cyano, hydroxy, --(CH.sub.2).sub.nNR.sup.8aR.sup.8b, --(CH.sub.2).sub.nC(O)R.sup.9, --(CH.sub.2).sub.nS(O).sub.mR.sup.9, --(CH.sub.2).sub.nS(O).sub.mNR.sup.8aR.sup.8b, --(CH.sub.2).sub.nN(R.sup.8a)S(O).sub.mR.sup.9, --(CH.sub.2).sub.nC(O)NR.sup.8aR.sup.8b, --(CH.sub.2).sub.nOC(O)R.sup.9, --(CH.sub.2).sub.nC(O)(CH.sub.2).sub.nOR.sup.9, or --(CH.sub.2).sub.nN(R.sup.8a)C(O)R.sup.9, (2) C.sub.1-6alkyl or C.sub.1-6alkoxy, both of which may be optionally substituted with 1-3 substituents selected from halogen, hydroxy and cyano, or; (3) 5- to 10-membered heteroaryl or 5- to 10-membered heterocyclic group, both of which may be optionally substituted with 1-3 substituents selected from halogen, hydroxy, cyano, trifluoromethyl, C.sub.1-6alkyl, C.sub.1-6alkoxy, --(CH.sub.2).sub.nNR.sup.8aR.sup.8b, --(CH.sub.2).sub.nC(O)R.sup.9, --(CH.sub.2).sub.nC(O)NR.sup.8aR.sup.8b, --(CH.sub.2).sub.nS(O).sub.mR.sup.9, --(CH.sub.2).sub.nS(O).sub.mNR.sup.8aR.sup.8b, --(CH.sub.2).sub.nN(R.sup.8a)S(O).sub.mR.sup.9, --(CH.sub.2).sub.nOC(O)R.sup.9, and --(CH.sub.2).sub.nN(R.sup.8a)C(O)R.sup.9; R.sup.8a and R.sup.8b are each independently hydrogen or C.sub.1-6alkyl; R.sup.9 is hydrogen or C.sub.1-6alkyl, wherein C.sub.1-6alkyl may be optionally substituted with 1-3 substituents selected from halogen, cyano, hydroxy, and --NR.sup.8aR.sup.8b; m is 0, 1 or 2; and n is 0-3. 2. The compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof: X and Y are each O; A and B are each CH; R.sup.1 is 6- to 10-membered aryl or 5- to 6-membered monocyclic heteroaryl, both of which may be optionally substituted with 1-3 R.sup.7a(s); R.sup.2 is 6- to 10-membered aryl, 5- to 6-membered monocyclic heteroaryl, or 9- to 10-membered fused heteroaryl, all of which may be optionally substituted with 1-3 R.sup.7b(s); R.sup.3 is hydrogen; R.sup.4 is hydrogen or C.sub.1-6alkyl, wherein C.sub.1-6alkyl may be optionally substituted with hydroxy; R.sup.7a and R.sup.8a are each independently (1) halogen, cyano, hydroxy, --(CH.sub.2).sub.nNR.sup.8aR.sup.8b, --(CH.sub.2).sub.nC(O)R.sup.9, --(CH.sub.2).sub.nS(O).sub.mR.sup.9, --(CH.sub.2).sub.nC(O)NR.sup.8aR.sup.8b, --C(O)(CH.sub.2).sub.nOR.sup.9, or --(CH.sub.2).sub.nN(R.sup.8a)C(O)R.sup.9, (2) C.sub.1-6alkyl or C.sub.1-6alkoxy, both of which may be optionally substituted with 1-3 substituents selected from halogen, hydroxy and cyano, or (3) 5- to 6-membered monocyclic heteroaryl or 5- to 6-membered monocyclic heterocyclic group, both of which may be optionally substituted with 1-3 substituents selected from halogen, hydroxy, cyano, trifluoromethyl, C.sub.1-6alkyl, C.sub.1-6alkoxy, --(CH.sub.2).sub.nNR.sup.8aR.sup.8b, --(CH.sub.2).sub.nC(O)R.sup.9, --(CH.sub.2).sub.nC(O)NR.sup.8aR.sup.8b, --(CH.sub.2).sub.nOC(O)R.sup.9, and --(CH.sub.2).sub.nN(R.sup.8a)C(O)R.sup.9; R.sup.8a and R.sup.8b are each independently hydrogen or C.sub.1-6alkyl; R.sup.9 is hydrogen or C.sub.1-6alkyl, wherein C.sub.1-6alkyl may be optionally substituted with 1-3 substituents selected from halogen, cyano, hydroxy, and --NR.sup.8aR.sup.8b; m is 0, 1 or 2; and n is 0-3. 3. The compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof: X and Y are each O; A and B are each CH; R.sup.1 is phenyl, pyridyl, or pyrimidyl, all of which may be optionally substituted with 1-3 R.sup.7a(s); R.sup.2 is phenyl, pyridyl, pyrimidyl, thienyl, pyrazolyl, indazolyl, indolyl, pyridopyrrolyl, pyrazolylpyridyl, or quinolyl, all of which may be optionally substituted with 1-3 R.sup.7b(s); R.sup.3 is hydrogen; R.sup.4 is hydrogen, methyl, ethyl or hydroxymethyl; R.sup.7a and R.sup.8a are each independently (1) cyano, hydroxy, trifluoromethyl, --NR.sup.8aR.sup.8b, --C(O)R.sup.9, --S(O).sub.mR.sup.9, --C(O)NR.sup.7aR.sup.7b, --C(O)(CH.sub.2).sub.nOR.sup.9, or --N(R.sup.8a)C(O)R.sup.9, (2) C.sub.1-6alkyl or C.sub.1-6alkoxy, both of which may be optionally substituted with 1-3 substituents selected from halogen, hydroxy and cyano, or (3) pyrrolyl, pyrazolyl, imidazolyl, piperidyl, piperazinyl, or morpholinyl, all of which may be optionally substituted with 1-3 substituents selected from halogen, hydroxy, cyano, trifluoromethyl, C.sub.1-6alkyl, C.sub.1-6alkoxy, --NR.sup.8aR.sup.8b, --C(O)R.sup.9, --C(O)NR.sup.8aR.sup.8b, --OC(O)R.sup.9, and --N(R.sup.8a)C(O)R.sup.9; R.sup.8a and R.sup.8b are each independently hydrogen or C.sub.1-6alkyl; R.sup.9 is hydrogen or C.sub.1-6alkyl, wherein C.sub.1-6alkyl may be optionally substituted with 1-3 substituents selected from halogen, cyano, and hydroxy; m is 0, 1 or 2. 4. The compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof: X and Y are each O; A and B are each CH; R.sup.1 is 5- to 6-membered monocyclic heterocyclic group, which may be optionally substituted with 1-3 R.sup.7a(s); R.sup.2 is 6- to 10-membered aryl, 5- to 6-membered monocyclic heteroaryl, or 9- to 10-membered fused heteroaryl, all of which may be optionally substituted with 1-3 R.sup.7b(s); R.sup.3 is hydrogen; R.sup.4 is hydrogen, methyl, or hydroxymethyl; R.sup.7a and R.sup.7b are each independently (1) cyano, hydroxy, --(CH.sub.2).sub.nNR.sup.8aR.sup.8b, --(CH.sub.2).sub.nC(O)R.sup.9, --(CH.sub.2).sub.nS(O).sub.mR.sup.9, --(CH.sub.2).sub.nC(O)NR.sup.7aR.sup.7b, --C(O)(CH.sub.2).sub.nOR.sup.9, or --(CH.sub.2).sub.nN(R.sup.8a)C(O)R.sup.9, (2) C.sub.1-6alkyl or C.sub.1-6alkoxy, both of which may be optionally substituted with 1-3 substituents selected from halogen, hydroxy and cyano, or (3) 5- to 6-membered monocyclic heteroaryl or 5- to 6-membered monocyclic heterocyclic group, both of which may be optionally substituted with 1-3 substituents selected from halogen, hydroxy, cyano, trifluoromethyl, C.sub.1-6alkyl, C.sub.1-6alkoxy, --(CH.sub.2).sub.nNR.sup.8aR.sup.8b, --(CH.sub.2).sub.mC(O)R.sup.9, --(CH.sub.2).sub.nC(O)NR.sup.8aR.sup.8b, --(CH.sub.2).sub.nOC(O)R.sup.9, and --(CH.sub.2).sub.nN(R.sup.8a)C(O)R.sup.9; R.sup.8a and R.sup.8b are each independently hydrogen or C.sub.1-6alkyl; R.sup.9 is hydrogen or C.sub.1-6alkyl, wherein C.sub.1-6alkyl may be optionally substituted with 1-3 substituents selected from halogen, cyano, hydroxy, and --NR.sup.8aR.sup.8b; m is 0, 1 or 2; and n is 0-3. 5. A compound selected from the group consisting of the following compounds, or a pharmaceutically acceptable salt or a stereoisomer thereof: ##STR00356## ##STR00357## ##STR00358## ##STR00359## ##STR00360## ##STR00361## ##STR00362## ##STR00363## ##STR00364## ##STR00365## ##STR00366## ##STR00367## ##STR00368## ##STR00369## ##STR00370## ##STR00371## ##STR00372## ##STR00373## ##STR00374## ##STR00375## ##STR00376## ##STR00377## ##STR00378## ##STR00379## ##STR00380## ##STR00381## 6. A compound selected from the group consisting of the following compounds, or a pharmaceutically acceptable salt or a stereoisomer thereof: ##STR00382## ##STR00383## ##STR00384## ##STR00385## ##STR00386## ##STR00387## ##STR00388## ##STR00389## ##STR00390## ##STR00391## ##STR00392## ##STR00393## ##STR00394## ##STR00395## ##STR00396## ##STR00397## ##STR00398## ##STR00399## ##STR00400## ##STR00401## ##STR00402## ##STR00403## ##STR00404## ##STR00405## ##STR00406## ##STR00407## ##STR00408## ##STR00409## ##STR00410## ##STR00411## ##STR00412## ##STR00413## ##STR00414## ##STR00415## ##STR00416## ##STR00417## ##STR00418## ##STR00419## ##STR00420## ##STR00421## ##STR00422## ##STR00423## ##STR00424## ##STR00425## ##STR00426## ##STR00427## ##STR00428## ##STR00429## ##STR00430## ##STR00431## ##STR00432## ##STR00433## ##STR00434## ##STR00435## ##STR00436## ##STR00437## 7. A pharmaceutical composition, containing the compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof and one or more pharmaceutically acceptable carriers, and optionally further containing one or more antitumor agents and immunosuppressants, wherein the antitumor agents and immunosuppressive agents are (1) anti-metabolites selected from capecitabine, gemcitabine and pemetrexed disodium; (2) growth factor inhibitors selected from pazopanib, imatinib, erlotinib, lapatinib, gefitinib and vandetanib; (3) antibodies selected from Herceptin and Avastin; (4) mitotic inhibitors selected from paclitaxel, vinorelbine, docetaxel and doxorubicin; (5) anti-tumor hormones selected from letrozole, tamoxifen, fulvestrant, flutamide and triptorelin; (6) alkylating agents selected from cyclophosphamide, nitrogen mustard, melphalan, chlorambucil and carmustine; (7) platinum metals selected from carboplatin, cisplatin and oxaliplatin; (8) topoisomerase inhibitors selected from camptothecin, topotecan and irinotecan; (9) immunosuppressants selected from everolimus, sirolimus and temsirolimus; (10) purine analogues selected from 6-mercaptopurine, 6-thioguanine and azathioprine; (11) antibiotics selected from rhzomorph D, daunorubicin, doxorubicin, mitoxantrone, bleomycin and plicamycin; or (12) adrenal cortex inhibitor which is aminoglutethimide. 8. A method for treating proliferative diseases, which comprises administering to a patient a therapeutically effective amount of the compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof. 9. The method of claim 8, wherein the proliferative diseases includes cancer and non-cancer diseases, wherein the cancer disease is selected from a brain tumor, lung cancer, non-small cell lung cancer, squamous cell carcinoma, bladder cancer, stomach cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, kidney cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, solid tumors, non-Hodgkin's lymphoma, glioma, glioblastoma multiforme, glio sarcoma, prostate cancer, thyroid carcinoma, genital tract carcinoma, carcinoma in situ, lymphoma, histiocytic lymphoma, neurofibromatosis, bone cancer, skin cancer, colon cancer, testicular cancer, small cell lung cancer, gastrointestinal stromal tumor, prostate tumor, mast cell tumor, multiple myeloma, melanoma, glioma glioblastoma, astrocytoma, neuroblastoma, sarcomas; and the non-cancer disease is selected from a skin disease or benign prostate hyperplasia.

Details for Patent 9,365,572

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2032-09-12
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2032-09-12
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2032-09-12